Search

Your search keyword '"Hrusovsky S"' showing total 19 results
Start Over Author "Hrusovsky S"
19 results on '"Hrusovsky S"'

1. The present and future disease burden of hepatitis C virus (HCV) infections with todayʼs treatment paradigm – volume 2

Author

Hatzakis, A., Chulanov, V., Gadano, A. C., Bergin, C., Ben-Ari, Z., Mossong, J., Schréter, I., Baatarkhuu, O., Acharya, S., Aho, I., Anand, A. C., Andersson, M. I., Arendt, V., Arkkila, P., Barclay, K., Bessone, F., Blach, S., Blokhina, N., Brunton, C. R., Choudhuri, G., Cisneros, L., Croes, E. A., Dahgwahdorj, Y. A., Dalgard, O., Daruich, J. R., Dashdorj, N. R., Davaadorj, D., de Knegt, R. J., de Vree, M., Estes, C., Flisiak, R., Gane, E., Gower, E., Halota, W., Henderson, C., Hoffmann, P., Hornell, J., Houlihan, D., Hrusovsky, S., Jarčuška, P., Kershenobich, D., Kostrzewska, K., Kristian, P., Leshno, M., Lurie, Y., Mahomed, A., Mamonova, N., Mendez-Sanchez, N., Norris, S., Nurmukhametova, E., Nymadawa, P., Oltman, M., Oyunbileg, J., Oyunsuren, Ts., Papatheodoridis, G., Pimenov, N., Prabdial-Sing, N., Prins, M., Radke, S., Rakhmanova, A., Razavi-Shearer, K., Reesink, H. W., Ridruejo, E., Safadi, R., Sagalova, O., Avila, Sanchez J. F., Sanduijav, R., Saraswat, V., Seguin-Devaux, C., Shah, S. R., Shestakova, I., Shevaldin, A., Shibolet, O., Silva, M. O., Sokolov, S., Sonderup, M., Souliotis, K., Spearman, C. W., Staub, T., Stedman, C., Strebkova, E. A., Struck, D., Sypsa, V., Tomasiewicz, K., Undram, L., van der Meer, A. J., van Santen, D., Veldhuijzen, I., Villamil, F. G., Willemse, S., Zuckerman, E., Zuure, F. R., Puri, P., and Razavi, H.

Published
2015
Full Text
View/download PDF

2. Strategies to manage hepatitis C virus (HCV) infection disease burden – volume 2

Author

Gane, E., Kershenobich, D., Seguin-Devaux, C., Kristian, P., Aho, I., Dalgard, O., Shestakova, I., Nymadawa, P., Blach, S., Acharya, S., Anand, A. C., Andersson, M. I., Arendt, V., Arkkila, P., Baatarkhuu, O., Barclay, K., Ben-Ari, Z., Bergin, C., Bessone, F., Blokhina, N., Brunton, C. R., Choudhuri, G., Chulanov, V., Cisneros, L., Croes, E. A., Dahgwahdorj, Y. A., Daruich, J. R., Dashdorj, N. R., Davaadorj, D., de Knegt, R. J., de Vree, M., Gadano, A. C., Gower, E., Halota, W., Hatzakis, A., Henderson, C., Hoffmann, P., Hornell, J., Houlihan, D., Hrusovsky, S., Jarčuška, P., Kostrzewska, K., Leshno, M., Lurie, Y., Mahomed, A., Mamonova, N., Mendez-Sanchez, N., Mossong, J., Norris, S., Nurmukhametova, E., Oltman, M., Oyunbileg, J., Oyunsuren, Ts., Papatheodoridis, G., Pimenov, N., Prins, M., Puri, P., Radke, S., Rakhmanova, A., Razavi, H., Razavi-Shearer, K., Reesink, H. W., Ridruejo, E., Safadi, R., Sagalova, O., Avila, Sanchez J. F., Sanduijav, R., Saraswat, V., Schréter, I., Shah, S. R., Shevaldin, A., Shibolet, O., Silva, M. O., Sokolov, S., Sonderup, M., Souliotis, K., Spearman, C. W., Staub, T., Stedman, C., Strebkova, E. A., Struck, D., Sypsa, V., Tomasiewicz, K., Undram, L., van der Meer, A. J., van Santen, D., Veldhuijzen, I., Villamil, F. G., Willemse, S., Zuckerman, E., Zuure, F. R., Prabdial-Sing, N., Flisiak, R., and Estes, C.

Published
2015
Full Text
View/download PDF

3. Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 2

Author

Saraswat, V., Norris, S., de Knegt, R. J., Avila, Sanchez J. F., Sonderup, M., Zuckerman, E., Arkkila, P., Stedman, C., Acharya, S., Aho, I., Anand, A. C., Andersson, M. I., Arendt, V., Baatarkhuu, O., Barclay, K., Ben-Ari, Z., Bergin, C., Bessone, F., Blach, S., Blokhina, N., Brunton, C. R., Choudhuri, G., Chulanov, V., Cisneros, L., Croes, E. A., Dahgwahdorj, Y. A., Dalgard, O., Daruich, J. R., Dashdorj, N. R., Davaadorj, D., de Vree, M., Estes, C., Flisiak, R., Gadano, A. C., Gane, E., Halota, W., Hatzakis, A., Henderson, C., Hoffmann, P., Hornell, J., Houlihan, D., Hrusovsky, S., Jarčuška, P., Kershenobich, D., Kostrzewska, K., Kristian, P., Leshno, M., Lurie, Y., Mahomed, A., Mamonova, N., Mendez-Sanchez, N., Mossong, J., Nurmukhametova, E., Nymadawa, P., Oltman, M., Oyunbileg, J., Oyunsuren, Ts., Papatheodoridis, G., Pimenov, N., Prabdial-Sing, N., Prins, M., Puri, P., Radke, S., Rakhmanova, A., Razavi, H., Razavi-Shearer, K., Reesink, H. W., Ridruejo, E., Safadi, R., Sagalova, O., Sanduijav, R., Schréter, I., Seguin-Devaux, C., Shah, S. R., Shestakova, I., Shevaldin, A., Shibolet, O., Sokolov, S., Souliotis, K., Spearman, C. W., Staub, T., Strebkova, E. A., Struck, D., Tomasiewicz, K., Undram, L., van der Meer, A. J., van Santen, D., Veldhuijzen, I., Villamil, F. G., Willemse, S., Zuure, F. R., Silva, M. O., Sypsa, V., and Gower, E.

Published
2015
Full Text
View/download PDF

4. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2

Author

Hatzakis, A. Chulanov, V. Gadano, A. C. Bergin, C. and Ben-Ari, Z. Mossong, J. Schreter, I. Baatarkhuu, O. and Acharya, S. Aho, I. Anand, A. C. Andersson, M. I. and Arendt, V. Arkkila, P. Barclay, K. Bessone, F. Blach, S. and Blokhina, N. Brunton, C. R. Choudhuri, G. Cisneros, L. and Croes, E. A. Dahgwahdorj, Y. A. Dalgard, O. Daruich, J. R. Dashdorj, N. R. Davaadorj, D. de Knegt, R. J. de Vree, M. Estes, C. Flisiak, R. Gane, E. Gower, E. and Halota, W. Henderson, C. Hoffmann, P. Hornell, J. and Houlihan, D. Hrusovsky, S. Jarcuska, P. Kershenobich, D. and Kostrzewska, K. Kristian, P. Leshno, M. Lurie, Y. and Mahomed, A. Mamonova, N. Mendez-Sanchez, N. Norris, S. and Nurmukhametova, E. Nymadawa, P. Oltman, M. Oyunbileg, J. and Oyunsuren, Ts. Papatheodoridis, G. Pimenov, N. and Prabdial-Sing, N. Prins, M. Radke, S. Rakhmanova, A. and Razavi-Shearer, K. Reesink, H. W. Ridruejo, E. Safadi, R. and Sagalova, O. Sanchez Avila, J. F. Sanduijav, R. and Saraswat, V. Seguin-Devaux, C. Shah, S. R. Shestakova, I. and Shevaldin, A. Shibolet, O. Silva, M. O. Sokolov, S. and Sonderup, M. Souliotis, K. Spearman, C. W. Staub, T. and Stedman, C. Strebkova, E. A. Struck, D. Sypsa, V. and Tomasiewicz, K. Undram, L. van der Meer, A. J. van Santen, D. Veldhuijzen, I. Villamil, F. G. Willemse, S. and Zuckerman, E. Zuure, F. R. Puri, P. Razavi, H.

Abstract

Morbidity and mortality attributable to chronic hepatitis C virus (HCV) infection are increasing in many countries as the infected population ages. Models were developed for 15 countries to quantify and characterize the viremic population, as well as estimate the number of new infections and HCV related deaths from 2013 to 2030. Expert consensus was used to determine current treatment levels and outcomes in each country. In most countries, viremic prevalence has already peaked. In every country studied, prevalence begins to decline before 2030, when current treatment levels were held constant. In contrast, cases of advanced liver disease and liver related deaths will continue to increase through 2030 in most countries. The current treatment paradigm is inadequate if large reductions in HCV related morbidity and mortality are to be achieved.

Published
2015

5. Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2

Author

Saraswat, V. Norris, S. de Knegt, R. J. Sanchez Avila, J. F. and Sonderup, M. Zuckerman, E. Arkkila, P. Stedman, C. and Acharya, S. Aho, I. Anand, A. C. Andersson, M. I. and Arendt, V. Baatarkhuu, O. Barclay, K. Ben-Ari, Z. and Bergin, C. Bessone, F. Blach, S. Blokhina, N. Brunton, C. R. Choudhuri, G. Chulanov, V. Cisneros, L. Croes, E. A. Dahgwahdorj, Y. A. Dalgard, O. Daruich, J. R. and Dashdorj, N. R. Davaadorj, D. de Vree, M. Estes, C. and Flisiak, R. Gadano, A. C. Gane, E. Halota, W. Hatzakis, A. Henderson, C. Hoffmann, P. Hornell, J. Houlihan, D. and Hrusovsky, S. Jarcuska, P. Kershenobich, D. Kostrzewska, K. Kristian, P. Leshno, M. Lurie, Y. Mahomed, A. and Mamonova, N. Mendez-Sanchez, N. Mossong, J. Nurmukhametova, E. Nymadawa, P. Oltman, M. Oyunbileg, J. Oyunsuren, Ts. and Papatheodoridis, G. Pimenov, N. Prabdial-Sing, N. Prins, M. Puri, P. Radke, S. Rakhmanova, A. Razavi, H. and Razavi-Shearer, K. Reesink, H. W. Ridruejo, E. Safadi, R. and Sagalova, O. Sanduijav, R. Schreter, I. Seguin-Devaux, C. Shah, S. R. Shestakova, I. Shevaldin, A. Shibolet, O. and Sokolov, S. Souliotis, K. Spearman, C. W. Staub, T. and Strebkova, E. A. Struck, D. Tomasiewicz, K. Undram, L. and van der Meer, A. J. van Santen, D. Veldhuijzen, I. Villamil, F. G. Willemse, S. Zuure, F. R. Silva, M. O. Sypsa, V. and Gower, E.

Abstract

Chronic hepatitis C virus (HCV) infection is a leading cause of liver related morbidity and mortality. In many countries, there is a lack of comprehensive epidemiological data that are crucial in implementing disease control measures as new treatment options become available. Published literature, unpublished data and expert consensus were used to determine key parameters, including prevalence, viremia, genotype and the number of patients diagnosed and treated. In this study of 15 countries, viremic prevalence ranged from 0.13% in the Netherlands to 2.91% in Russia. The largest viremic populations were in India (8666000 cases) and Russia (4162000 cases). In most countries, males had a higher rate of infections, likely due to higher rates of injection drug use (IDU). Estimates characterizing the infected population are critical to focus screening and treatment efforts as new therapeutic options become available.

Published
2015

6. Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2

Author

Gane, E. Kershenobich, D. Seguin-Devaux, C. Kristian, P. and Aho, I. Dalgard, O. Shestakova, I. Nymadawa, P. Blach, S. Acharya, S. Anand, A. C. Andersson, M. I. Arendt, V. and Arkkila, P. Baatarkhuu, O. Barclay, K. Ben-Ari, Z. and Bergin, C. Bessone, F. Blokhina, N. Brunton, C. R. and Choudhuri, G. Chulanov, V. Cisneros, L. Croes, E. A. and Dahgwahdorj, Y. A. Daruich, J. R. Dashdorj, N. R. Davaadorj, D. de Knegt, R. J. de Vree, M. Gadano, A. C. Gower, E. and Halota, W. Hatzakis, A. Henderson, C. Hoffmann, P. and Hornell, J. Houlihan, D. Hrusovsky, S. Jarcuska, P. and Kostrzewska, K. Leshno, M. Lurie, Y. Mahomed, A. and Mamonova, N. Mendez-Sanchez, N. Mossong, J. Norris, S. and Nurmukhametova, E. Oltman, M. Oyunbileg, J. Oyunsuren, Ts. and Papatheodoridis, G. Pimenov, N. Prins, M. Puri, P. and Radke, S. Rakhmanova, A. Razavi, H. Razavi-Shearer, K. and Reesink, H. W. Ridruejo, E. Safadi, R. Sagalova, O. and Sanchez Avila, J. F. Sanduijav, R. Saraswat, V. Schreter, I. and Shah, S. R. Shevaldin, A. Shibolet, O. Silva, M. O. and Sokolov, S. Sonderup, M. Souliotis, K. Spearman, C. W. and Staub, T. Stedman, C. Strebkova, E. A. Struck, D. Sypsa, V. Tomasiewicz, K. Undram, L. van der Meer, A. J. van Santen, D. Veldhuijzen, I. Villamil, F. G. Willemse, S. and Zuckerman, E. Zuure, F. R. Prabdial-Sing, N. Flisiak, R. and Estes, C.

Abstract

The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 15 countries, and the relative impact of two scenarios was considered: (i) increased treatment efficacy while holding the treated population constant and (ii) increased treatment efficacy and increased annual treated population. Increasing levels of diagnosis and treatment, in combination with improved treatment efficacy, were critical for achieving substantial reductions in disease burden. In most countries, the annual treated population had to increase several fold to achieve the largest reductions in HCV-related morbidity and mortality. This suggests that increased capacity for screening and treatment will be critical in many countries. Birth cohort screening is a helpful tool for maximizing resources. In most of the studied countries, the majority of patients were born between 1945 and 1985.

Published
2015

10. [Cost-effectiveness analysis of the treatment of chronic hepatitis C]

Author

Joliot E, Vanlemmens C, Kerleau M, Le Gales C, Mc, Woronoff-Lemsi, Ya, Flori, Seror V, Hrusovsky S, Elisabeth Monnet, Bresson-Hadni S, and Jp, Miguet

Subjects
Adult, Liver Cirrhosis, Male, Time Factors, Adolescent, Cost-Benefit Analysis, Interferon-alpha, Middle Aged, Antiviral Agents, Hepatitis C, Hospitalization, Humans, Female, Aged, Hepatitis, Chronic, Retrospective Studies
Abstract

Chronic active hepatitis C is an important public health issue because of its prevalence, evolution, and overall cost. Treatment by recombinant alpha-interferon is both expensive and exacting and its effectiveness is limited. We report the results of a cost-effectiveness analysis of alpha-interferon treatment in patients with chronic active hepatitis C.Direct medical costs of caring for patients with chronic active hepatitis C and its complications, based on treatment or no treatment, were assessed with retrospective data collected from the files of 137 hospital patients. Seventy-seven patients were treated with alpha-interferon between 1988 and 1994. The overall costs of caring for chronic active hepatitis C patients, without treatment or with alpha-interferon treatment (3 millions units three times a week) for 6 months (strategy A), 12 months (strategy B), or 12 months but discontinuing treatment when there was no response (strategy C), was reported and compared to the respective effectiveness of each.With an actualization rate of 5%, the real overall cost of caring for a chronic active hepatitis C patient was 143290 FF. Considering the contraindication rate (15%), the treatment acceptance (85%), the response rate to treatment (50%), and the prolonged response rate (25 to 30%), treating patients with strategy A induced a real overall cost of caring to 140731 FF to avoid 0.11 cases of cirrhosis, to 150277 FF to avoid 0.13 cases of cirrhosis with strategy B, and to 136947 FF to avoid 0.13 cases of cirrhosis with strategy C.Alpha-interferon treatment in patients with chronic active hepatitis C provides a long-term saving compared to cases which receive no treatment. Strategy C was the most cost-effective, inducing the reduction of both the number of cases of cirrhosis and the cost of care.

11. New ore structures in the northern part of the Rudnany district.

Author

Hudacek J., Fabian M., Hrusovsky S., Hudacek J., Fabian M., and Hrusovsky S.

Abstract

The Rudnany ore district is the most important source of complex Fe, Cu, Hg, Sb, Bi and BaSO4 ore in Czechoslovakia. After exploration in recent years, new ore structures have been found together with new mineralisation types in the northern part of the Rudnany district., The Rudnany ore district is the most important source of complex Fe, Cu, Hg, Sb, Bi and BaSO4 ore in Czechoslovakia. After exploration in recent years, new ore structures have been found together with new mineralisation types in the northern part of the Rudnany district.

12. Liver transplantation in Central Europe.

Author

Trunecka P, Gerlei Z, Lisik W, Skladany L, Fronek J, Hrusovsky S, and Małkowski P

Abstract

Introduction: Transplant hepatologists convened in Warsaw on 20-21 November 2015 at a meeting of the Initiative Group for Central European Hepatologic Collaboration to exchange their experience in liver transplantation in their respective countries., Material and Methods: The description is based on narration of individual country representatives, supplemented by data from additional queries, and from publicly accessible sources., Results: Liver transplantation programs were launched, in the Czech Republic in 1983, in Poland in 1990 (paediatric) followed by the adult program 1994; the first liver transplant in Hungary was performed in 1995, with Slovakia launching its liver transplantation program in 2008. Currently, there are 2 centres for liver transplantation in Slovakia, 1 centre in Hungary, 6 centres in Poland, and 2 centres in the Czech Republic. The rates of liver transplantation correspond to the number of cadaveric donations being the highest in the Czech Republic (15.8 per million population) and the lowest in Slovakia (4.2 per million population) (2014 data). Live donation is utilized systematically in Poland. Indications vary from country to country, but the 3 most frequent ones include hepatitis C and B cirrhosis, alcoholic cirrhosis, and cholestatic liver disorders. There is a growing incidence of hepatocellular carcinoma among adult liver transplant recipients. Biliary atresia and hereditary diseases are the most frequent indications among children. Hungary became a member of Eurotransplant, other countries are not a part of any international organization for organ sharing., Conclusions: Despite some differences, liver transplant programs seem to be compatible honouring the same values and principles universal to liver transplant programs in most parts of the world.

Published
2016
Full Text
View/download PDF

13. Brain natriuretic peptide (BNP) in differential diagnosis of dyspnea.

Author

Belovicova M, Kinova S, and Hrusovsky S

Subjects
Aged, Aged, 80 and over, Biomarkers blood, Diagnosis, Differential, Female, Heart Failure complications, Humans, Male, Middle Aged, Sensitivity and Specificity, Dyspnea etiology, Heart Failure diagnosis, Natriuretic Peptide, Brain blood
Abstract

Background: The differentiation of congestive heart failure from pulmonary cause of dyspnea is of extreme importance in patients presenting with acute shortness of breath. It seems that the use of B-type natriuretic peptide (BNP) can speed up the diagnostic process significantly., Material and Methods: 79 patients (46 men - 58.2%, average 71.9, range 43-92; 33 women - 41.8%, average 75.5, range 51-93). In each of them we measured BNP concentrations by means of rapid fluorescent immunoassay., Results: We divided the patients according to BNP results into two groups: BNP positive and BNP negative. There were 28 BNP negative patients -35.40% (13 men, 15 women). BNP positive patients (51) were divided into NYHA I-IV groups in accordance with BNP results., Conclusion: The rapid, highly sensitive and specific measurement of BNP concentrations in the patients with dyspnea can significantly help to differentiate the cardiac and pulmonary causes of dyspnea (Tab. 1, Fig. 1, Ref. 24).

Published
2005

14. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.

Author

Pijak MR, Gazdik F, and Hrusovsky S

Subjects
Black or African American, Humans, Interferon alpha-2, RNA, Viral analysis, Recombinant Proteins, Antiviral Agents therapeutic use, Hepacivirus classification, Hepatitis C, Chronic drug therapy, Hepatitis C, Chronic virology, Interferon-alpha therapeutic use, Polyethylene Glycols therapeutic use, Ribavirin therapeutic use
Published
2004
Full Text
View/download PDF

15. The best type of trial.

Author

Pijak MR, Gazdik F, and Hrusovsky S

Subjects
Humans, Outcome Assessment, Health Care, Patient Selection, Product Surveillance, Postmarketing, Observation, Randomized Controlled Trials as Topic
Published
2004
Full Text
View/download PDF

16. Primary disease recurrence after liver transplantation for alveolar echinococcosis: long-term evaluation in 15 patients.

Author

Bresson-Hadni S, Koch S, Beurton I, Vuitton DA, Bartholomot B, Hrusovsky S, Heyd B, Lenys D, Minello A, Becker MC, Vanlemmens C, Mantion GA, and Miguet JP

Subjects
Adult, Aged, Anthelmintics therapeutic use, Benzimidazoles therapeutic use, Brain diagnostic imaging, Brain parasitology, Echinococcosis diagnostic imaging, Echinococcosis parasitology, Echinococcosis, Hepatic drug therapy, Echinococcosis, Hepatic mortality, Echinococcosis, Pulmonary diagnostic imaging, Echinococcosis, Pulmonary parasitology, Female, Humans, Liver parasitology, Longitudinal Studies, Lung diagnostic imaging, Lung parasitology, Male, Middle Aged, Postoperative Period, Recurrence, Tomography, X-Ray Computed, Echinococcosis, Hepatic surgery, Liver Transplantation
Abstract

Between 1986 and 1991, 21 patients received liver grafts in our center for incurable alveolar echinococcosis (AE). The aim of this study was to analyze the long-term results in 15 of these 21 patients who survived more than 1 year after undergoing a liver transplantation (LT). The follow-up, mainly aimed at the diagnosis of recurrence, consisted of repeated radiological and specific immunological investigations. The role of pre- and post-LT benzimidazole (BZM) therapy was also evaluated. Among the 15 patients, 8 patients had a palliative LT related to previously known pulmonary AE metastases and/or inextirpable abdominal parasitic foci. In the 7 remaining patients, LT was considered curative. In June 1998, the mean follow-up duration was 96 months (range: 28-138 months). Five late deaths occurred, 2 of them were directly related to residual AE. A reinfection of the graft was observed in 4 patients. Preoperative BZM therapy seemed useful in preventing or delaying the parasitic recurrence. Post-LT BZM was able to stabilize and even to reduce residual AE. The anti-Em2 enzyme-linked immunosorbent assay (ELISA), which is the standard test used in patient follow-up after partial liver resection for AE, did not appear useful in detecting recurrence here; however, an ELISA, using a crude heterologous antigen (Echinococcus granulosus) allowed early diagnosis of residual AE. In conclusion, primary disease recurrence is not rare after LT for AE. Immunosuppressive therapy may favor larval growth in extrahepatic sites; therefore, an extensive extrahepatic radiological check-up has to be performed before LT. BZM therapy seems to stabilize residual foci. Anti-Eg immunoglobulin G (IgG) follow-up is the most useful test for early diagnosis of parasite recurrence.

Published
1999
Full Text
View/download PDF

17. [Acute cytolytic hepatitis caused by coumarin. 2 cases].

Author

Koch S, Beurton I, Bresson-Hadni S, Monnot B, Hrusovsky S, Becker MC, Vanlemmens C, Carbillet JP, and Miguet JP

Subjects
Acute Disease, Adult, Anticoagulants adverse effects, Coumarins therapeutic use, Female, Humans, Middle Aged, Venous Insufficiency drug therapy, Anticoagulants therapeutic use, Chemical and Drug Induced Liver Injury etiology, Coumarins adverse effects
Abstract

Coumarin is a drug which is extensively used to treat lymphedema. We report two cases of acute hepatitis probably due to coumarin. Two women, 40 year and 45 year-old, were treated with 90 mg/d of coumarin for 5 months. Clinical features included jaundice, pruritus, and diarrhea. A marked increase in serum aminotransferases was observed (ALT: 30 and 100 times the upper limit of normal, respectively). Coumarin withdrawal was rapidly followed by a favorable outcome in both cases. Rechallenge in one case induced a relapse of symptoms and liver test abnormalities. Coumarin can induce acute cytolytic hepatitis.

Published
1997

18. [Cost-effectiveness analysis of the treatment of chronic hepatitis C].

Author

Joliot E, Vanlemmens C, Kerleau M, Le Gales C, Woronoff-Lemsi MC, Flori YA, Seror V, Hrusovsky S, Monnet E, Bresson-Hadni S, and Miguet JP

Subjects
Adolescent, Adult, Aged, Antiviral Agents therapeutic use, Female, Hepatitis C physiopathology, Hepatitis C therapy, Hepatitis, Chronic physiopathology, Hepatitis, Chronic therapy, Hospitalization economics, Humans, Interferon-alpha therapeutic use, Liver Cirrhosis economics, Liver Cirrhosis prevention & control, Male, Middle Aged, Retrospective Studies, Time Factors, Antiviral Agents economics, Cost-Benefit Analysis, Hepatitis C economics, Hepatitis, Chronic economics, Interferon-alpha economics
Abstract

Objectives: Chronic active hepatitis C is an important public health issue because of its prevalence, evolution, and overall cost. Treatment by recombinant alpha-interferon is both expensive and exacting and its effectiveness is limited. We report the results of a cost-effectiveness analysis of alpha-interferon treatment in patients with chronic active hepatitis C., Methods: Direct medical costs of caring for patients with chronic active hepatitis C and its complications, based on treatment or no treatment, were assessed with retrospective data collected from the files of 137 hospital patients. Seventy-seven patients were treated with alpha-interferon between 1988 and 1994. The overall costs of caring for chronic active hepatitis C patients, without treatment or with alpha-interferon treatment (3 millions units three times a week) for 6 months (strategy A), 12 months (strategy B), or 12 months but discontinuing treatment when there was no response (strategy C), was reported and compared to the respective effectiveness of each., Results: With an actualization rate of 5%, the real overall cost of caring for a chronic active hepatitis C patient was 143290 FF. Considering the contraindication rate (15%), the treatment acceptance (85%), the response rate to treatment (50%), and the prolonged response rate (25 to 30%), treating patients with strategy A induced a real overall cost of caring to 140731 FF to avoid 0.11 cases of cirrhosis, to 150277 FF to avoid 0.13 cases of cirrhosis with strategy B, and to 136947 FF to avoid 0.13 cases of cirrhosis with strategy C., Conclusion: Alpha-interferon treatment in patients with chronic active hepatitis C provides a long-term saving compared to cases which receive no treatment. Strategy C was the most cost-effective, inducing the reduction of both the number of cases of cirrhosis and the cost of care.

Published
1996

19. Human hepatocyte growth factor serum levels in early stages after orthotopic liver transplantation.

Author

Hrusovsky S, Tsubouchi H, Remy-Martin A, Jouvenot M, Adessi GL, Rouget C, Mantion G, Heyd B, Chabod P, and Bresson S

Subjects
Adult, Aged, Alanine Transaminase blood, Alkaline Phosphatase blood, Aspartate Aminotransferases blood, Bilirubin blood, Biomarkers blood, Blood Coagulation Factors analysis, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Middle Aged, Time Factors, Hepatocyte Growth Factor blood, Liver Transplantation physiology
Published
1994

Catalog

Books, media, physical & digital resources
See catalog results